CRISPR Therapeutics develops gene‑based medicines using its proprietary CRISPR/Cas9 gene‑editing platform. The company focuses on translating CRISPR/Cas9 into therapeutic programs and advancing them to the clinic. It has strategic collaborations with Vertex Pharmaceuticals and Bayer AG to develop CRISPR‑based therapeutics. Headquarters are in Basel, Switzerland, with R&D operations in Cambridge, Massachusetts. The company plans to use recent proceeds to advance current and future programs to the clinic and to expand its research and development organization in Cambridge. Recent financing activity included an oversubscribed additional closing to its Series B round, bringing total proceeds to nearly $140 million. CRISPR Therapeutics focuses on translating CRISPR-Cas9 gene‑editing technology into therapies for serious human diseases. The company has translational development programs across multiple disease areas with collaborators in Europe and the U.S. It maintains operations in Basel, Switzerland; Stevenage, UK; and Cambridge, Massachusetts. Management intends to use recent proceeds to advance current and future programs toward the clinic and to expand the research and development organization in Cambridge. The company emphasizes curing diseases at the molecular level by leveraging CRISPR-Cas9 in its drug-development efforts. CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human genetic diseases. The company focuses on using the Cas9 enzyme, programmable with RNA, to cut DNA at targeted sites to delete, insert or correct genes and address both recessive and dominant disorders. CRISPR Therapeutics has assembled a founding team of world-renowned academics and clinicians, including Drs. Daniel Anderson, Emmanuelle Charpentier, Chad Cowan, Craig Mello and Matthew Porteus. It has secured rights to foundational intellectual property covering the use of CRISPR-Cas9 in human therapeutics, in-licensing the technology from Dr. Charpentier. The company says the funding and the team’s expertise will allow it to translate the technology into new gene medicines that could cure serious genetic diseases at the molecular level. CRISPR Therapeutics is based in Basel, Switzerland, with operations in London, UK.

Total raised

$127M

Funding rounds

4

Latest round

Series B

Latest activity

Jun 2016